BioSyent Inc.

106 articles about BioSyent Inc.

• BioSyent Announces Extension of RepaGyn® and Proktis-M® Agreement

  4/15/2024

  BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc. (“BioSyent Pharma”), has extended its Exclusive License and Distribution Agreement with its European partner for the RepaGyn® and Proktis-M® products, extending BioSyent Pharma’s exclusive Canadian rights to these products until 2032.

• BioSyent to Present at 2024 Bloom Burton & Co. Healthcare Investor Conference

  4/10/2024

  BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be presenting at the upcoming 2024 Bloom Burton & Co. Healthcare Investor Conference.

• BioSyent to Present at LD Micro New York Investor Conference

  4/1/2024

  BioSyent Inc. announces that Mr. René Goehrum, President and CEO of BioSyent, will be presenting in person at the LD Micro Invitational XIV Conference in New York City on Tuesday, April 9th at 8:00am EDT.

• BioSyent Announces Grant of Restricted Share Units - March 27, 2024

  3/27/2024

  BioSyent Inc. announces that its Board of Directors has approved a grant of 66,020 Restricted Share Units “RSUs” to certain directors, officers, management, and employees of the Company pursuant to the Company’s Restricted Share Unit Plan.

• BioSyent Releases Financial Results for Fourth Quarter and Full Year 2023

  3/13/2024

  BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the fourth quarter (Q4) and full year (FY) ended December 31, 2023.

• BioSyent Schedules Fourth Quarter and Full Year 2023 Earnings Release for March 13, 2024

  3/6/2024

  BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and full year ended December 31, 2023 on Wednesday, March 13th after market hours.

• BioSyent Named to 2024 TSX Venture 50

  2/21/2024

  BioSyent Inc. is pleased to announce that it has been named to the 2024 TSX Venture 50 list as one of the top performers on the TSX Venture Exchange.

• BioSyent Declares First Quarter 2024 Dividend

  2/6/2024

  BioSyent Inc. is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.045 per common share, payable in Canadian Dollars on March 15, 2024, to shareholders of record at the close of business on February 29, 2024.

• BioSyent Announces the Availability of Gelclair® in Canada

  11/20/2023

  BioSyent Inc. is pleased to announce that its subsidiary, BioSyent Pharma Inc., has commenced the first shipments of its new oncology supportive care product, Gelclair®, to wholesalers in Canada.

• BioSyent Releases Q3 and YTD 2023 Financial Results

  11/16/2023

  BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q3) and nine months (YTD) ended September 30, 2023.

• BioSyent Declares Fourth Quarter 2023 Dividend

  11/15/2023

  BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable in Canadian Dollars on December 15, 2023, to shareholders of record at the close of business on November 30, 2023.

• BioSyent Schedules Q3 and YTD 2023 Earnings Release for November 16, 2023

  11/9/2023

  BioSyent Inc. will be reporting its financial results for the three and nine months ended September 30, 2023 on Thursday, November 16, 2023 before market hours.

• BioSyent Releases Q2 and H1 2023 Financial Results

  8/22/2023

  BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and six months ended June 30, 2023.

• BioSyent Declares Third Quarter 2023 Dividend

  8/22/2023

  BioSyent Inc. is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable in Canadian Dollars on September 15, 2023, to shareholders of record at the close of business on August 31, 2023.

• BioSyent Schedules Q2 and H1 2023 Earnings Release for August 22, 2023

  8/15/2023

  BioSyent Inc. will be reporting its financial results for the three and six months ended June 30, 2023 on Tuesday, August 22, 2023 after market close.

• BioSyent Pharma to Introduce Gelclair® at AHNS 11th International Conference on Head and Neck Cancer

  7/6/2023

  BioSyent Pharma Inc., a subsidiary of BioSyent Inc., is attending the American Head and Neck Society 11th International Conference on Head and Neck Cancer in Montreal, Quebec on July 8-12, 2023 to promote Gelclair®, its new oncology supportive care product.

• BioSyent Announces Long-term Extension of Cathejell® Agreement

  6/20/2023

  BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc. (“BioSyent Pharma”), has extended its License, Distribution and Supply Agreement with its European partner for the Cathejell ® product, extending BioSyent Pharma’s exclusive Canadian rights to Cathejell ® until 2034.

• BioSyent Announces Approval of New Product

  5/31/2023

  BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has received regulatory approval from Health Canada for a new oncology supportive care product.

• BioSyent Releases Financial Results for Q1 2023

  5/26/2023

  BioSyent Inc. released its financial results for the three months ended March 31, 2023.

• BioSyent Declares Second Quarter 2023 Dividend

  5/25/2023

  BioSyent Inc. is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable in Canadian Dollars on June 15, 2023, to shareholders of record at the close of business on June 2, 2023.